<?xml version="1.0" encoding="UTF-8"?>
<p>The primary management of IBD involves treating uncontrolled inflammation with a significant number of patients requiring immune‐based therapies.
 <xref rid="apt15779-bib-0004" ref-type="ref">
  <sup>4</sup>
 </xref> In the last decade, there has been a considerable expansion of the therapeutic armamentarium for patients with IBD to include immunomodulators, TNF antagonists, non‐TNF‐targeted biologics and targeted small molecule therapies.
 <xref rid="apt15779-bib-0005" ref-type="ref">
  <sup>5</sup>
 </xref> However, these therapies, in addition to malnutrition which can complicate IBD, may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications.
 <xref rid="apt15779-bib-0006" ref-type="ref">
  <sup>6</sup>
 </xref>
</p>
